Cost and operational impact of promoting upfront GeneXpert MTB/RIF test referrals for presumptive pediatric tuberculosis patients in India.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 30 11 2018
accepted: 18 03 2019
entrez: 2 4 2019
pubmed: 2 4 2019
medline: 14 1 2020
Statut: epublish

Résumé

Outreach and promotion programs are essential to ensuring uptake of new public health interventions and guidelines. We assessed the costs and operation dynamics of outreach and promotion efforts for up front Xpert MTB/RIF (Xpert) testing for pediatric presumptive tuberculosis (TB) patients in four major Indian cities. Xpert test costs were assessed as weighted average per-test costs based on the daily workload dynamics matched by test volume specific Xpert unit cost at each study site. Costs of outreach programs to recruit health providers to refer pediatric patients for Xpert testing were assessed as cost per referral for each quarter based on total program costs and referral data. All costs were assessed in the health service provider's perspective and expressed in 2015 USD. Weighted average per-test costs ranged from $14.71 to $17.81 at the four laboratories assessed. Differences between laboratories were associated with unused testing capacity and/or frequencies of overtime work to cope with increasing demand and same-day testing requirements. Outreach activities generated between 825 and 2,065 Xpert testing referrals on average each quarter across the four study sites, translating into $0.63 to $2.55 per patient referred. Overall outreach costs per referral decreased with time, stabilizing at an average cost of $1.10, and demonstrated a clear association with increased referrals. Xpert test and outreach program costs within and across study sites were mainly driven by the dynamics of Xpert testing demand resulting from the combined outreach activities. However, these increases in demand required considerable overtime work resulting in additional costs and operational challenges at the study laboratories. Therefore, careful laboratory operational adjustment should be evaluated at target areas in parallel to the anticipated demand from the Xpert referral outreach program scale-up in other Indian regions.

Sections du résumé

BACKGROUND
Outreach and promotion programs are essential to ensuring uptake of new public health interventions and guidelines. We assessed the costs and operation dynamics of outreach and promotion efforts for up front Xpert MTB/RIF (Xpert) testing for pediatric presumptive tuberculosis (TB) patients in four major Indian cities.
METHODS
Xpert test costs were assessed as weighted average per-test costs based on the daily workload dynamics matched by test volume specific Xpert unit cost at each study site. Costs of outreach programs to recruit health providers to refer pediatric patients for Xpert testing were assessed as cost per referral for each quarter based on total program costs and referral data. All costs were assessed in the health service provider's perspective and expressed in 2015 USD.
RESULTS
Weighted average per-test costs ranged from $14.71 to $17.81 at the four laboratories assessed. Differences between laboratories were associated with unused testing capacity and/or frequencies of overtime work to cope with increasing demand and same-day testing requirements. Outreach activities generated between 825 and 2,065 Xpert testing referrals on average each quarter across the four study sites, translating into $0.63 to $2.55 per patient referred. Overall outreach costs per referral decreased with time, stabilizing at an average cost of $1.10, and demonstrated a clear association with increased referrals.
CONCLUSIONS
Xpert test and outreach program costs within and across study sites were mainly driven by the dynamics of Xpert testing demand resulting from the combined outreach activities. However, these increases in demand required considerable overtime work resulting in additional costs and operational challenges at the study laboratories. Therefore, careful laboratory operational adjustment should be evaluated at target areas in parallel to the anticipated demand from the Xpert referral outreach program scale-up in other Indian regions.

Identifiants

pubmed: 30933997
doi: 10.1371/journal.pone.0214675
pii: PONE-D-18-34370
pmc: PMC6443160
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0214675

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Health Policy Plan. 1999 Dec;14(4):374-81
pubmed: 10787653
Int J Tuberc Lung Dis. 2017 Apr 1;21(4):375-380
pubmed: 28284251
PLoS Med. 2011 Nov;8(11):e1001120
pubmed: 22087078
Health Policy Plan. 2000 Jun;15(2):230-4
pubmed: 10837047
Health Econ. 2016 Feb;25 Suppl 1:53-66
pubmed: 26763594
PLoS One. 2018 Feb 28;13(2):e0193194
pubmed: 29489887

Auteurs

Sanjay Sarin (S)

Foundation for Innovative New Diagnostics, New Delhi, India.

Sophie Huddart (S)

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
McGill International TB Centre, Montreal, Quebec, Canada.

Neeraj Raizada (N)

Foundation for Innovative New Diagnostics, New Delhi, India.

Debadutta Parija (D)

Foundation for Innovative New Diagnostics, New Delhi, India.

Aakshi Kalra (A)

Foundation for Innovative New Diagnostics, New Delhi, India.

Raghuram Rao (R)

Central TB Division, Government of India, New Delhi, India.

Virender Singh Salhotra (VS)

Central TB Division, Government of India, New Delhi, India.

Sunil D Khaparde (SD)

Central TB Division, Government of India, New Delhi, India.

Catharina Boehme (C)

Foundation for Innovative New Diagnostics, Geneva, Switzerland.

Claudia M Denkinger (CM)

Foundation for Innovative New Diagnostics, Geneva, Switzerland.

Hojoon Sohn (H)

Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH